Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
BioInvent International AB ( (SE:BINV) ) has shared an announcement.
BioInvent International AB announced promising preliminary data from its ongoing Phase 2a study of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL). The data showed a 63% objective response rate among the first eight patients, with two complete responses and three partial responses, indicating potential improvements in treatment outcomes and resistance management. The combination therapy has been well tolerated, and BioInvent plans to advance its clinical development, highlighting the potential impact on NHL treatment and the company’s position in cancer immunotherapy.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel and first-in-class antibodies for cancer immunotherapy. The company has five drug candidates in six ongoing clinical programs targeting hematological cancer and solid tumors. BioInvent’s proprietary F.I.R.S.T™ technology platform aids in identifying targets and antibodies, fueling its clinical development pipeline and offering licensing and partnering opportunities. The company also generates revenue through research collaborations, license agreements, and antibody production for third parties.
Average Trading Volume: 89,227
Current Market Cap: SEK2.16B
For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.